• Ferrostatin-1: Selective Ferroptosis Inhibitor in Disease...

  2025-10-02

  Ferrostatin-1 (Fer-1) stands apart as a selective ferroptosis inhibitor, empowering researchers to precisely dissect iron-dependent oxidative cell death in cancer, neurodegeneration, and ischemic injury models. This article delivers protocol enhancements, experimental insights, and troubleshooting strategies for leveraging Fer-1 in both foundational discovery and translational research.

• Ferrostatin-1: Selective Ferroptosis Inhibitor for Advanc...

  2025-10-01

  Ferrostatin-1 (Fer-1) stands out as a potent selective ferroptosis inhibitor, enabling precise dissection of iron-dependent oxidative cell death across cancer, neurodegenerative, and ischemic injury models. This article details optimized workflows, troubleshooting, and real-world applications, positioning Fer-1 as an indispensable tool for translational research targeting caspase-independent cell death.

• Ferrostatin-1: Precision Modulation of Ferroptosis in Dis...

  2025-09-30

  Explore the advanced role of Ferrostatin-1 (Fer-1) as a selective ferroptosis inhibitor in dissecting lipid peroxidation pathways, with a focus on experimental design, mechanistic specificity, and translational insights. This article delves deeper than standard reviews, providing researchers with unique strategies for leveraging Fer-1 in complex disease models.

• Ferrostatin-1 (Fer-1): Precision Tools for Targeting Ferr...

  2025-09-29

  Explore the unique potential of Ferrostatin-1 (Fer-1) as a selective ferroptosis inhibitor in dissecting iron-dependent oxidative cell death across cancer and neurodegenerative models. This article offers novel, translational insights into integrating Fer-1 with metabolic and autophagic pathway research.

• Ferrostatin-1: Precision Inhibition of Ferroptosis in Adv...

  2025-09-28

  Explore how Ferrostatin-1 (Fer-1), a selective ferroptosis inhibitor, enables precise control of iron-dependent oxidative cell death in research. This article unveils unique insights into mechanistic applications, advanced disease modeling, and translational research opportunities.

• ABT-263 (Navitoclax): Precision Targeting of Apoptosis vi...

  2025-09-27

  Explore how ABT-263 (Navitoclax), a potent Bcl-2 family inhibitor, enables nuanced, mechanistically informed apoptosis research. This article uniquely integrates advanced insights into mitochondrial signaling, RNA Pol II-dependent cell death, and resistance profiling for cancer biology.

• Aprotinin in Translational Hemodynamics: Mechanistic Insi...

  2025-09-26

  Explore the multifaceted role of aprotinin, a potent serine protease inhibitor, in translational hemodynamics, with novel insights into red blood cell membrane biomechanics and advanced surgical blood management. Discover how bovine pancreatic trypsin inhibitor drives innovation in cardiovascular disease research.

• Torin2: Unlocking Selective mTOR Inhibition for Precision...

  2025-09-25

  Explore Torin2, a potent mTOR inhibitor, in the context of emerging apoptosis signaling and mitochondrial pathways in cancer research. This article offers a unique, in-depth analysis of Torin2’s role in dissecting regulated cell death, advancing beyond conventional PI3K/Akt/mTOR pathway insights.

• Cyclopamine: Advanced Insights into Hedgehog Pathway Inhi...

  2025-09-24

  Explore Cyclopamine as a potent Hedgehog signaling inhibitor and Smoothened receptor antagonist, with a focus on its mechanistic depth, unique applications in cancer research, and emerging insights from comparative developmental models. This article offers advanced scientific analysis and practical considerations beyond conventional reviews.

• Phenacetin in Advanced Intestinal Organoid Pharmacokinetics

  2025-09-23

  Explore the application of phenacetin, a non-opioid analgesic, in cutting-edge pharmacokinetic studies utilizing hiPSC-derived intestinal organoids. This article examines solubility, biotransformation, and model selection challenges for scientific research use.

• br Parkinson s Disease and the immune system Parkinson s

  2025-03-03

  

  Parkinson’s Disease and the immune system Parkinson’s Disease (PD) is the second most common neurodegenerative disorder, after Alzheimer’s, which affects 10 million people globally and is characterized by rigidity, bradykinesia, tremors, and gait instability (O’sullivan et al., 2007). The patholo

• Though we have proved that VA could suppress hepatic

  2025-03-03

  

  Though, we have proved that VA could suppress hepatic gluconeogenesis, the mechanisms of VA on gluconeogenesis in vivo and in vitro remain unclear. AMP-activated protein kinase (AMPK), which is called an energy receptor enzyme, is widely expressed in liver and other tissues [23]. AMPK has become ano

• br Conclusions The following are the supplementary data rela

  2025-03-03

  

  Conclusions The following are the supplementary data related to this article. Author contributions Conflict of interest Funding sources This work was supported by the Canadian Institutes of Health Research [grant: MOP-79470]. Introduction Sperm cells undergo a number of physical and

• Very recently Niessen et al have described

  2025-03-03

  

  Very recently, Niessen et al. have described the resensitizing effect of MB327 on nAChR performing solid-supported membrane (SSM)-based electrophysiological experiments (Niessen et al., 2016) using plasma membrane preparations obtained from Torpedo californica. These findings validated and underline

• 2-deoxy-d-ribose br Concluding remarks Autophagy ensures cel

  2025-03-03

  

  Concluding remarks Autophagy ensures cell homeostasis and survival through the continuous degradation/recycling of intracellular components. It can also represent a conserved, cell-intrinsic, defense mechanism against invading pathogens, including viruses. The autophagy process can be activated r

16318 records 20/1088 page Previous Next First page 上5页 1617181920 下5页 Last page